These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 29948020)

  • 21. [Circulating Tumor DNA (ctDNA) Detection Using BEAMing and Its Clinical Significance.].
    Nakamura K
    Rinsho Byori; 2016 May; 64(4):400-406. PubMed ID: 29182806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of circulating tumor DNA in the management of early-stage lung cancer.
    Zhao H; Chen KZ; Hui BG; Zhang K; Yang F; Wang J
    Thorac Cancer; 2018 May; 9(5):509-515. PubMed ID: 29528556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution.
    Casanova-Salas I; Aguilar D; Cordoba-Terreros S; Agundez L; Brandariz J; Herranz N; Mas A; Gonzalez M; Morales-Barrera R; Sierra A; Soriano-Navarro M; Cresta P; Mir G; Simonetti S; Rodrigues G; Arce-Gallego S; Delgado-Serrano L; Agustí I; Castellano-Sanz E; Mast R; de Albert M; Celma A; Santamaria A; Gonzalez L; Castro N; Suanes MDM; Hernández-Losa J; Nonell L; Peinado H; Carles J; Mateo J
    Cancer Cell; 2024 Jul; 42(7):1301-1312.e7. PubMed ID: 38981440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.
    Khagi Y; Goodman AM; Daniels GA; Patel SP; Sacco AG; Randall JM; Bazhenova LA; Kurzrock R
    Clin Cancer Res; 2017 Oct; 23(19):5729-5736. PubMed ID: 28972084
    [No Abstract]   [Full Text] [Related]  

  • 29. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracellular vesicle-based drug delivery in cancer immunotherapy.
    Najafi S; Majidpoor J; Mortezaee K
    Drug Deliv Transl Res; 2023 Nov; 13(11):2790-2806. PubMed ID: 37261603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.
    Li RY; Liang ZY
    Chin Med J (Engl); 2020 Oct; 133(20):2476-2485. PubMed ID: 32960843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review ctDNA and Breast Cancer.
    Clatot F
    Recent Results Cancer Res; 2020; 215():231-252. PubMed ID: 31605232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating or tissue microRNAs and extracellular vesicles as potential lung cancer biomarkers: a systematic review.
    Song Y; Yu X; Zang Z; Zhao G
    Int J Biol Markers; 2018 Jan; 33(1):3-9. PubMed ID: 29076520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
    Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
    Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid biopsy of circulating tumor DNA and biosensor applications.
    Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
    Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
    Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
    Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
    Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmable DNA Circuit-Facilitated Determination of Circulating Extracellular Vesicle PD-L1 for Lung Cancer Diagnosis and Immunotherapy Response Prediction.
    Bo B; Li W; Li J; Han C; Fang Q; Yang M; Ni J; Zhou C
    ACS Appl Mater Interfaces; 2023 Apr; 15(14):17696-17704. PubMed ID: 36978260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.